Veristat Expands its Expertise and Scale across Biopharma and Medtech
Acquires Swiss-based multi-disciplinary consultancy SFL (Solutions for Life Sciences) to accelerate...
Veristat Supported Marketing Applications for 12% of all FDA Novel Drug Approvals in 2021
Bridging the Gap between Trial and Treatment by Supporting the Approval of Several Novel Therapies...
Veristat Strengthens Regulatory Capabilities Across Europe and UK
Acquires Drug Development and Regulation (DDR), a regulatory consultancy led by former senior...
Veristat Appoints Colleen Pelton Chief Talent Officer
Global Talent Executive to Advance Company’s Commitment to a Best-in-class Workforce
Veristat Announces New Investment Partner—WindRose Health Investors
Recapitalization Will Accelerate Strategic Growth to Help Sponsors Save and Improve the Lives of...
Veristat Congratulates Origin Biosciences for FDA Approval
Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry during the Week of Rare...
Veristat Expands Biometrics Capabilities by Acquiring SQN Clinical
Builds on a shared pedigree of data management, statistics and programming excellence across all...
Veristat Supported Marketing Applications for 10% of all FDA Novel Drug Approvals in 2020
Strengthening its Track Record of Successful Client Regulatory Approval Outcomes
SOUTHBOROUGH, MA...
Veristat Launches Business Operations in Spain and Names Dr. Montserrat Barceló to Vice President, Europe
Leading the Organic and Acquisition Growth of Veristat Operations Throughout Europe
Veristat Named a Top Patient Recruitment Company by PharmaTech Outlook
Delivering A Patient-Centric Approach to Recruitment and Retention for Clinical Trials
...
